Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Deferred Taxes (2020 - 2025)

Historic Deferred Taxes for Autolus Therapeutics (AUTL) over the last 6 years, with Q3 2025 value amounting to -$13000.0.

  • Autolus Therapeutics' Deferred Taxes fell 10773.81% to -$13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 22941.92%. This contributed to the annual value of $185000.0 for FY2024, which is 8123.73% down from last year.
  • As of Q3 2025, Autolus Therapeutics' Deferred Taxes stood at -$13000.0, which was down 10773.81% from -$384000.0 recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Deferred Taxes ranged from a high of $1.0 million in Q3 2022 and a low of -$487000.0 during Q1 2025
  • For the 5-year period, Autolus Therapeutics' Deferred Taxes averaged around $33000.0, with its median value being -$13000.0 (2025).
  • In the last 5 years, Autolus Therapeutics' Deferred Taxes surged by 33519.31% in 2022 and then plummeted by 41891.89% in 2025.
  • Over the past 5 years, Autolus Therapeutics' Deferred Taxes (Quarter) stood at -$276000.0 in 2021, then decreased by 15.58% to -$319000.0 in 2022, then soared by 246.08% to $466000.0 in 2023, then tumbled by 130.26% to -$141000.0 in 2024, then skyrocketed by 90.78% to -$13000.0 in 2025.
  • Its Deferred Taxes stands at -$13000.0 for Q3 2025, versus -$384000.0 for Q2 2025 and -$487000.0 for Q1 2025.